Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 92 clinical trials
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)

This study will assess the efficacy and safety of pembrolizumab plus enzalutamide plus ADT versus placebo plus enzalutamide plus ADT in participants with mHSPC. The primary hypothesis is that in

  • 272 views
  • 18 Jan, 2021
  • 199 locations
  • 0 views
  • 23 Jan, 2021
  • 2496 views
  • 01 Jan, 2021
  • 210 locations
Study of Pembrolizumab (MK-3475) Combination Therapies in Metastatic Castration-Resistant Prostate Cancer (MK-3475-365/KEYNOTE-365)

be nine cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort

bone lesions
prostate adenocarcinoma
docetaxel
androgen suppression
bone scan
  • 0 views
  • 12 Dec, 2020
  • 11 locations
Investigation of Radium-223 Dichloride (Xofigo) a Treatment That Gives Off Radiation That Helps Kill Cancer Cells Compared to a Treatment That Inactivates Hormones (New Antihormonal Therapy NAH) in Patients With Prostate Cancer That Has Spread to the Bone Getting Worse on or After Earlier NAH

study will be either abiraterone acetate (Zytiga) (plus prednisone/prednisolone) or enzalutamide (Xtandi). Both of them are standard approved medications which are used in the treatment of advanced

  • 0 views
  • 01 Jan, 2021
  • 140 locations
Enzalutamide With Lu PSMA-617 Versus Enzalutamide Alone in Men With Metastatic Castration-resistant Prostate Cancer

This phase 2 randomised clinical trial will investigate the activity and safety of adding Lu-PSMA to enzalutamide in patients with metastatic castrate resistant prostate cancer (mCRPC) not

prostate adenocarcinoma
renal function
neutrophil count
liver metastases
bone scan
  • 0 views
  • 25 Jan, 2021
  • 4 locations
Combination Study of AZD5069 and Enzalutamide.

ACE is a multi-centre proof of concept Phase I/II trial of the CXCR2 antagonist AZD5069, administered in combination with enzalutamide, in patients with metastatic castration resistant prostate

  • 52 views
  • 26 Jan, 2021
  • 3 locations
Study to Evaluate CORT125281 in Combination With Enzalutamide in Patients With mCRPC

CORT125281 in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) to identify a recommended dose (RD) for Phase 2 studies.

prostate adenocarcinoma
progressive disease
luteinizing hormone
hormone releasing
testosterone
  • 129 views
  • 16 Dec, 2020
  • 16 locations
A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

This is a randomized, multi-center, double-blind, Phase III study of radium-223 plus enzalutamide or darolutamide compared to enzalutamide or darolutamide treatment plus placebo.

other imaging modalities
prostate adenocarcinoma
neutrophil count
adenocarcinoma
bone scan
  • 0 views
  • 25 Jan, 2021
  • 1 location
A Study of Patient Preference Between ODM-201 and Enzalutamide in Men With Metastatic Castrate-resistant Prostate Cancer

To assess patient preference between ODM-201 and enzalutamide by patient preference questionnaire

  • 3 views
  • 24 Jan, 2021
  • 1 location